Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + nintedanib
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Capecitabine + nintedanib is an investigational oral combination therapy evaluated primarily for refractory metastatic colorectal cancer. Capecitabine is a prodrug of 5-fluorouracil, functioning as an antimetabolite that inhibits DNA synthesis in rapidly dividing tumor cells. Nintedanib is a small molecule tyrosine kinase inhibitor targeting multiple angiokinase receptors, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). This dual approach aims to inhibit tumor cell proliferation and angiogenesis. Clinical studies have shown the combination to be well tolerated with promising efficacy compared to other therapies in heavily pretreated colorectal cancer patients[1][4][5].
- Brand names
- Xeloda (capecitabine)Ofev (nintedanib)Vargatef (nintedanib)
- Other names
- nintedanib + capecitabine
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR4 (Vascular endothelial growth factor Receptor-3)PDGFRA (Platelet-derived growth factor receptor alpha)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on capecitabine + nintedanib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + nintedanib.